BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 28652243)

  • 1. Clinical Pathways: Recommendations for Putting Patients at the Center of Value-Based Care.
    Abrahams E; Balch A; Goldsmith P; Kean M; Miller AM; Omenn G; Sonet E; Sprandio J; Tyne C; Westrich K
    Clin Cancer Res; 2017 Aug; 23(16):4545-4549. PubMed ID: 28652243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Impact of Alternative Payment Models on Oncology Innovation and Patient Care.
    Miller AM; Omenn GS; Kean MA
    Clin Cancer Res; 2016 May; 22(10):2335-41. PubMed ID: 27087022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accelerating the delivery of patient-centered, high-quality cancer care.
    Abrahams E; Foti M; Kean MA
    Clin Cancer Res; 2015 May; 21(10):2263-7. PubMed ID: 25901079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The patient-centered medical home in oncology: from concept to reality.
    Page RD; Newcomer LN; Sprandio JD; McAneny BL
    Am Soc Clin Oncol Educ Book; 2015; ():e82-9. PubMed ID: 25993243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Community Oncology Medical Homes: Physician-Driven Change to Improve Patient Care and Reduce Costs.
    Waters TM; Webster JA; Stevens LA; Li T; Kaplan CM; Graetz I; McAneny BL
    J Oncol Pract; 2015 Nov; 11(6):462-7. PubMed ID: 26220931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A health services research agenda to fully integrate cancer rehabilitation into oncology care.
    Pergolotti M; Alfano CM; Cernich AN; Yabroff KR; Manning PR; de Moor JS; Hahn EE; Cheville AL; Mohile SG
    Cancer; 2019 Nov; 125(22):3908-3916. PubMed ID: 31390063
    [No Abstract]   [Full Text] [Related]  

  • 7. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Budget impact and cost-effectiveness: can we afford precision medicine in oncology?
    Doble B
    Scand J Clin Lab Invest Suppl; 2016; 245():S6-S11. PubMed ID: 27426412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Private payers and cancer care: land of opportunity.
    Klein I; Kolodziej M
    J Oncol Pract; 2014 Jan; 10(1):15-9. PubMed ID: 24084888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies For Clinical Implementation: Precision Oncology At Three Distinct Institutions.
    Nadauld LD; Ford JM; Pritchard D; Brown T
    Health Aff (Millwood); 2018 May; 37(5):751-756. PubMed ID: 29733728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The science of precision prevention of cancer.
    Vineis P; Wild CP
    Lancet Oncol; 2017 Aug; 18(8):997-998. PubMed ID: 28759370
    [No Abstract]   [Full Text] [Related]  

  • 12. Equity in cancer care: pathways, protocols, and guidelines.
    DeMartino JK; Larsen JK
    J Natl Compr Canc Netw; 2012 Oct; 10 Suppl 1():S1-9. PubMed ID: 23042831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The "value" of value in gynecologic oncology practice in the United States: Society of Gynecologic Oncology evidence-based review and recommendations.
    Cohn DE; Ko E; Meyer LA; Wright JD; Temkin SM; Foote J; Jones NL; Havrilesky LJ
    Gynecol Oncol; 2017 Apr; 145(1):185-191. PubMed ID: 28258763
    [No Abstract]   [Full Text] [Related]  

  • 14. Value Based Care and Patient-Centered Care: Divergent or Complementary?
    Tseng EK; Hicks LK
    Curr Hematol Malig Rep; 2016 Aug; 11(4):303-10. PubMed ID: 27262855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opening the black box: the impact of an oncology management program consisting of level I pathways and an outbound nurse call system.
    Hoverman JR; Klein I; Harrison DW; Hayes JE; Garey JS; Harrell R; Sipala M; Houldin S; Jameson MD; Abdullahpour M; McQueen J; Nelson G; Verrilli DK; Neubauer M
    J Oncol Pract; 2014 Jan; 10(1):63-7. PubMed ID: 24443735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received.
    Schnipper LE; Davidson NE; Wollins DS; Blayney DW; Dicker AP; Ganz PA; Hoverman JR; Langdon R; Lyman GH; Meropol NJ; Mulvey T; Newcomer L; Peppercorn J; Polite B; Raghavan D; Rossi G; Saltz L; Schrag D; Smith TJ; Yu PP; Hudis CA; Vose JM; Schilsky RL
    J Clin Oncol; 2016 Aug; 34(24):2925-34. PubMed ID: 27247218
    [No Abstract]   [Full Text] [Related]  

  • 17. Potential approaches to sustainable, long-lasting payment reform in oncology.
    American Society of Clinical Oncology
    J Oncol Pract; 2014 Jul; 10(4):254-8. PubMed ID: 24737874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Precision Medicine in Oncology II: Economics of Targeted Agents and Immuno-Oncology Drugs.
    Huntington SF; Davidoff AJ; Gross CP
    J Clin Oncol; 2020 Feb; 38(4):351-358. PubMed ID: 31804866
    [No Abstract]   [Full Text] [Related]  

  • 19. Value and payment for oncology in the United States.
    Robinson JC
    Ann Pharm Fr; 2013 Sep; 71(5):285-90. PubMed ID: 24075699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. War and peace? The oncologic and the palliative care perspective on personalized cancer treatment in a patient with advanced cancer.
    Masel EK; Schur S; Posch D; Weixler D; Meran JG; Schmidinger M; Watzke HH
    Wien Klin Wochenschr; 2015 Aug; 127(15-16):635-8. PubMed ID: 25986998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.